Cingulate Inc. (NASDAQ:CING - Free Report) - Equities researchers at Zacks Small Cap issued their Q3 2024 EPS estimates for shares of Cingulate in a report issued on Monday, August 26th. Zacks Small Cap analyst J. Vandermosten expects that the company will earn ($3.03) per share for the quarter. Zacks Small Cap also issued estimates for Cingulate's Q4 2024 earnings at ($3.20) EPS, FY2024 earnings at ($16.00) EPS, FY2025 earnings at ($3.25) EPS and FY2026 earnings at ($0.32) EPS.
Cingulate Trading Down 19.0 %
Shares of NASDAQ:CING traded down $1.88 during trading on Wednesday, hitting $8.00. The stock had a trading volume of 856,063 shares, compared to its average volume of 1,442,085. Cingulate has a 12-month low of $1.80 and a 12-month high of $187.20. The stock has a 50-day simple moving average of $2.50 and a two-hundred day simple moving average of $1.50.
Cingulate (NASDAQ:CING - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($5.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.64) by $0.17.
Hedge Funds Weigh In On Cingulate
An institutional investor recently bought a new position in Cingulate stock. Armistice Capital LLC bought a new position in shares of Cingulate Inc. (NASDAQ:CING - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 490,000 shares of the company's stock, valued at approximately $157,000. Armistice Capital LLC owned about 6.67% of Cingulate at the end of the most recent reporting period. 41.31% of the stock is owned by hedge funds and other institutional investors.
About Cingulate
(
Get Free Report)
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
Read More
Before you consider Cingulate, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cingulate wasn't on the list.
While Cingulate currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
